Vitiligo is an acquired depigmentation disorder of great cosmetic importance, affecting 1% to 4% of the general population. Narrowband UV-B and calcipotriene are new additions to the armamentarium of vitiligo treatment. Earlier, in a double-blind right-left comparative study, we have shown that the combination of psoralen–UV-A and sun exposure (PUVASOL) with calcipotriene has been found to be effective and repigmentation was better than with PUVASOL alone.1 Based on this background, recently we tried the combination of caclipotriene and narrowband UV-B in a patient with vitiligo and had good results. Herein we highlight the possible therapeutic potential of this combined treatment modality in vitiligo.